# OnCo record paper-checkmate-743-lancet-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-743-lancet-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-743-lancet-2021" ;
  schema:name "CheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma"@en ;
  schema:description "Dual immunotherapy with nivolumab and ipilimumab lengthened survival compared with platinum-pemetrexed chemotherapy in pleural mesothelioma, the first improvement in first-line treatment in almost twenty years, with the largest gain in non-epithelioid tumours."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-743-lancet-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(20)32714-8>, <https://pubmed.ncbi.nlm.nih.gov/33485464/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(20)32714-8> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Baas P, Scherpereel A, Nowak AK, et al." ;
  onco:cancers <https://onco.cc/cancers/pleural-mesothelioma/>, <https://onco.cc/cancers/peritoneal-mesothelioma/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-743/> ;
  onco:journals <https://onco.cc/journals/lancet/> .